Gene Therapy Vaccine Articles & Analysis
20 news found
With the industry rushing to harness the potential of advanced therapeutics — from gene therapies to mRNA vaccines — most key breakthroughs are gated by a singular challenge: delivering the payload. ...
In many research applications, such as gene expression studies, vaccine development, and gene therapy, transfection—the process of introducing nucleic acids into cells—is an essential step. ...
This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and vaccines. Lipid Nanoparticles have become a groundbreaking delivery mechanism within the biopharmaceutical sector. ...
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern ...
ByNuvonis
This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, ...
This funding supports Virica’s collaboration with the National Research Council of Canada’s (NRC) Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable version of AAV-LPL, a gene therapy being developed for people with debilitating lipoprotein lipase deficiency (LPLD). ...
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using ...
Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. ...
“This investment accelerates our capacity to help companies and organizations overcome production shortfalls and improve the efficiencies of their viral-based therapies, cell therapies, and vaccine candidates.” “Innovators and contract development and manufacturing companies alike are struggling to reliably produce sufficient ...
While the accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing, it has also highlighted the need to find ways to quickly and reliably develop and manufacture transformative drugs and therapies at scale. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. ...
Novasep's viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. ...
The site will expand the company's clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments as well as mRNA vaccines. ...
Construction of the 25,000 ft2 facility will commence in Q4 2020 and will be dedicated to the production of viral vectors used in cell and gene therapies, vaccines and oncolytic products. When completed, the facility will provide Matica Bio’s clients with comprehensive viral vector development, manufacturing and analytical services ...
Featuring highly automated technology in a fully scalable, mixed-use space, the site will serve as a strategic logistics hub for shipping by road or air and its central location will help expedite clinical trial therapies to patients. In Weil am Rhein, the new 9,600-square-foot/890-square-meter cryocenter provides specialized ultra-low-temperature, cryogenic storage and cold ...
The $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines. Construction of the new 290,000-square-foot facility is expected to be completed in 2022. ...
“Over the next five years we’ll see precision medicine approvals go beyond the targeted therapy space of oncogenic drivers of cancer and transition to the immunotherapy space,” he says. ...
Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com. ...